Boehringer Ingelheim Corporation’s New Once-Daily Striverdi* (Olodaterol) Respimat® Gains Approval in First EU Countries

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Boehringer Ingelheim today announced the successful completion of the review process of the Marketing Authorisation Application for Striverdi® Respimat® in the European Union for patients with chronic obstructive pulmonary disease (COPD).

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC